



ADVISORY NOTE

Banning Menthol in Tobacco Products

WHO Study Group on Tobacco Product Regulation (TobReg)



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Advisory note: banning menthol in tobacco products: WHO study Group on Tobacco Product Regulation (TobReg).

1.Smoking – adverse effects. 2.Tobacco – toxicity. 3.Tobacco – legislation. 4.Menthol. I.World Health Organization. II.WHO Study Group on Tobacco Product Regulation.

ISBN 978 92 4 151033 2

(NLM classification: QV 137)

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed by the WHO Document Production Services, Geneva, Switzerland

ADVISORY NOTE

Banning Menthol in Tobacco Products

WHO Study Group on Tobacco Product Regulation (TobReg)



**World Health
Organization**

Contents

Participants in the eighth meeting of the WHO Study Group on Tobacco Product Regulation	6
Preface	9
Acknowledgements	11
1. Introduction	12
2. Use of menthol in tobacco products	14
2.1 Form and method of application in tobacco	14
2.2 Menthol content of cigarettes	15
2.3 Menthol content of non-combusted tobacco	16
2.4 Summary	16
3. Patterns of use of menthol	17
3.1 Prevalence of menthol tobacco use	17
3.2 Demographic patterns of menthol use	18
3.2.1 Youth and young adults	18
3.2.2 Women	19
3.2.3 Racial and ethnic minorities	19
3.2.4 People with psychiatric disorders	20
3.3 Trends in menthol cigarette use	20
3.4 Summary	21
4. Marketing of menthol	22
4.1 Pricing and retailing of menthol and non-menthol cigarettes	22
4.2 Promotions, advertising and packaging	23
4.3 Health reassurance messages	23
4.4 “Youthfulness”, sociability and group belonging	24
4.5 Target groups (youth, women, specific racial or ethnic groups)	24
4.6 Product differences	25
4.7 Summary	26
5. Consumer perceptions of menthol	27
5.1 Taste perception and sensory evaluation	27
5.2 Perceptions of harm	28
5.3 Roles of branding and labelling in taste perception and sensory evaluation	29
5.4 Favourable views of menthol and tobacco use	29
5.5 Summary	30

6. Physiological effects of menthol	31
6.1 Reduced harshness or irritation	31
6.2 Sensory stimulation	32
6.3 Respiratory effects	33
6.4 Conditioned reinforcement	34
6.5 Nicotinic acetylcholine receptors	34
6.6 Nicotine metabolism and bioavailability	35
6.7 Genetic differences	36
6.8 Summary	37
7. Health outcomes	38
7.1 Biomarkers of exposure	38
7.2 Smoking behaviour and topography	39
7.3 Toxicity	39
7.4 Cancer risk	40
7.5 Non-cancer disease risk	41
7.6 Summary	41
8. Effects of smoking behaviour, dependence and quitting	42
8.1 Initiation	42
8.2 Switching	43
8.3 Progression to regular use	44
8.4 Strength of addiction	44
8.5 Intention to quit or seek treatment	46
8.6 Cessation outcomes and relapse rates	46
8.7 Effects on use of other tobacco products and of drugs	47
8.8 Summary	48
9. Regulation of menthol	49
9.1 Existing regulatory control	49
9.2 Support for regulation	50
9.3 Challenges to regulation	51
9.4 Potential effects of a menthol ban	51
9.5 Summary	53
10. Conclusions	54
11. Recommendations	56
12. References	57

Participants in the eighth meeting of the WHO Study Group on Tobacco Product Regulation

Rio de Janeiro, Brazil, 9–11 December 2015

Members

Dr D.L. Ashley, Director, Office of Science, Center for Tobacco Products, Food and Drug Administration, Rockville, Maryland, United States of America

Professor O.A. Ayo-Yusuf, Dean, School of Oral Health Sciences, Sefako Makgatho Health Sciences University, Pretoria, South Africa

Professor A.R. Boobis, Biochemical Pharmacology, Centre for Pharmacology and Therapeutics, Department of Medicine, Imperial College, London; Director, Public Health England Toxicology Unit, Imperial College, London, United Kingdom

Professor Mike Daube, Professor of Health Policy, Curtin University, Director, Public Health Advocacy Institute, Perth, Western Australia, Australia

Dr M.V. Djordjevic, Program Director/Project Officer, Tobacco Control Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, United States of America

Dr P. Gupta, Director, Healis Sekhsaria Institute for Public Health, Mumbai, India

Dr S.K. Hammond, Professor of Environmental Health Sciences, School of Public Health, University of California, Berkeley, California, United States of America

Dr D. Hatsukami, Professor of Psychiatry, University of Minnesota, Minneapolis, Minnesota, United States of America

Dr A. Opperhuizen, Director, Office for Risk Assessment and Research, Utrecht, The Netherlands

Dr G. Zaatari (Chair), Professor and Chairman, Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon

**Key facilitators of the WHO Framework Convention on Tobacco Control
Conference of the Parties Working Group on Articles 9 and 10**

Ms Ana Claudia Bastos de Andrade, Head of Tobacco Products Control Department, ANVISA, Rio de Janeiro, Brazil

Dr Katja Broomen, Policy Officer, Tobacco Control team, European Commission, Directorate General Health and Food Safety, Unit D4, Substances of Human Origin and Tobacco Control, Brussels, Belgium

Mr D. Choinière, Director, Tobacco Products Regulatory Office, Controlled Substances and Tobacco Directorate, Health Canada, Ottawa, Ontario, Canada

Mrs Nalan Yazicioglu, Tobacco and Alcohol Market Regulatory Authority, Ankara, Turkey

Mr Irfan Disiliz, Board Member, Tobacco and Alcohol Market Regulatory Authority, Ankara, Turkey

Presenters

Ms N.P. Cheah, Director, Cosmetics and Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore

Professor G. Connolly, Professor of Research, Northeastern Law School, Boston, Massachusetts, United States of America

Professor T. Eissenberg, Professor of Psychology and Co-director, Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, Virginia, United States of America

Professor E. Fernández, Head, Tobacco Control Unit, Catalan Institute of Oncology, Bellvitge Institute of Biomedical Research, Associate Professor of Epidemiology and Public Health, University of Barcelona, Barcelona, Spain

Dr P. Richter, Deputy Chief, Tobacco and Volatile Branch, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Dr A. Shihadeh, American University of Beirut, Beirut, Lebanon

Dr R. Talhout, National Institute for Public Health and Environment (RIVM), Centre for Health Protection, Bilthoven, The Netherlands

Mr G.F. Wayne, California, United States of America

Secretariat of the WHO Framework Convention on Tobacco Control

Dr C. Audera-Lopez, World Health Organization, Geneva, Switzerland

WHO Secretariat

(Prevention of Noncommunicable Diseases, Geneva, Switzerland)

Ms M. Aryee-Quansah, Administrative Assistant, Tobacco Free Initiative

Dr A. Peruga, Programme Manager, Tobacco Free Initiative

Ms G. Vestal, Technical Officer (Legal), Tobacco Free Initiative

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27003

